dpp-4 assay buffer Search Results


90
Bachem dpp-4 assay buffer
Linagliptin (LGT) has neutral effects on body weight and aortic advanced glycation end-products (AGE). a WD feeding for 4 months resulted in significant weight gain in both the cohorts. b Plasma <t>DPP-4</t> activity was significantly decreased with LGT treatment. c AGE immunostaining in aorta was significantly increased in WDC. LGT treatment did not decrease it significantly. Quantification and representative images shown. Values are mean ± SE. CDC control diet control, CDL control diet linagliptin, WDC western diet control, WDL western diet linagliptin. Post-hoc comparisons within a time point; *p < 0.05 CDC vs WDC; # p < 0.05 CDC vs CDL; † p < 0.05 WDC vs WDL. Scale bars represent 50 mμ
Dpp 4 Assay Buffer, supplied by Bachem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dpp-4 assay buffer/product/Bachem
Average 90 stars, based on 1 article reviews
dpp-4 assay buffer - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Cayman Chemical dpp-4 assay
Linagliptin (LGT) has neutral effects on body weight and aortic advanced glycation end-products (AGE). a WD feeding for 4 months resulted in significant weight gain in both the cohorts. b Plasma <t>DPP-4</t> activity was significantly decreased with LGT treatment. c AGE immunostaining in aorta was significantly increased in WDC. LGT treatment did not decrease it significantly. Quantification and representative images shown. Values are mean ± SE. CDC control diet control, CDL control diet linagliptin, WDC western diet control, WDL western diet linagliptin. Post-hoc comparisons within a time point; *p < 0.05 CDC vs WDC; # p < 0.05 CDC vs CDL; † p < 0.05 WDC vs WDL. Scale bars represent 50 mμ
Dpp 4 Assay, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dpp-4 assay/product/Cayman Chemical
Average 90 stars, based on 1 article reviews
dpp-4 assay - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

93
R&D Systems anti dpp4
Linagliptin (LGT) has neutral effects on body weight and aortic advanced glycation end-products (AGE). a WD feeding for 4 months resulted in significant weight gain in both the cohorts. b Plasma <t>DPP-4</t> activity was significantly decreased with LGT treatment. c AGE immunostaining in aorta was significantly increased in WDC. LGT treatment did not decrease it significantly. Quantification and representative images shown. Values are mean ± SE. CDC control diet control, CDL control diet linagliptin, WDC western diet control, WDL western diet linagliptin. Post-hoc comparisons within a time point; *p < 0.05 CDC vs WDC; # p < 0.05 CDC vs CDL; † p < 0.05 WDC vs WDL. Scale bars represent 50 mμ
Anti Dpp4, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti dpp4/product/R&D Systems
Average 93 stars, based on 1 article reviews
anti dpp4 - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

90
Abnova human recombinant dpp4 solution
Linagliptin (LGT) has neutral effects on body weight and aortic advanced glycation end-products (AGE). a WD feeding for 4 months resulted in significant weight gain in both the cohorts. b Plasma <t>DPP-4</t> activity was significantly decreased with LGT treatment. c AGE immunostaining in aorta was significantly increased in WDC. LGT treatment did not decrease it significantly. Quantification and representative images shown. Values are mean ± SE. CDC control diet control, CDL control diet linagliptin, WDC western diet control, WDL western diet linagliptin. Post-hoc comparisons within a time point; *p < 0.05 CDC vs WDC; # p < 0.05 CDC vs CDL; † p < 0.05 WDC vs WDL. Scale bars represent 50 mμ
Human Recombinant Dpp4 Solution, supplied by Abnova, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human recombinant dpp4 solution/product/Abnova
Average 90 stars, based on 1 article reviews
human recombinant dpp4 solution - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Promega dppiv-glo™ subtrate
Linagliptin (LGT) has neutral effects on body weight and aortic advanced glycation end-products (AGE). a WD feeding for 4 months resulted in significant weight gain in both the cohorts. b Plasma <t>DPP-4</t> activity was significantly decreased with LGT treatment. c AGE immunostaining in aorta was significantly increased in WDC. LGT treatment did not decrease it significantly. Quantification and representative images shown. Values are mean ± SE. CDC control diet control, CDL control diet linagliptin, WDC western diet control, WDL western diet linagliptin. Post-hoc comparisons within a time point; *p < 0.05 CDC vs WDC; # p < 0.05 CDC vs CDL; † p < 0.05 WDC vs WDL. Scale bars represent 50 mμ
Dppiv Glo™ Subtrate, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dppiv-glo™ subtrate/product/Promega
Average 90 stars, based on 1 article reviews
dppiv-glo™ subtrate - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Promega dpp4-glo protease assay
Linagliptin (LGT) has neutral effects on body weight and aortic advanced glycation end-products (AGE). a WD feeding for 4 months resulted in significant weight gain in both the cohorts. b Plasma <t>DPP-4</t> activity was significantly decreased with LGT treatment. c AGE immunostaining in aorta was significantly increased in WDC. LGT treatment did not decrease it significantly. Quantification and representative images shown. Values are mean ± SE. CDC control diet control, CDL control diet linagliptin, WDC western diet control, WDL western diet linagliptin. Post-hoc comparisons within a time point; *p < 0.05 CDC vs WDC; # p < 0.05 CDC vs CDL; † p < 0.05 WDC vs WDL. Scale bars represent 50 mμ
Dpp4 Glo Protease Assay, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dpp4-glo protease assay/product/Promega
Average 90 stars, based on 1 article reviews
dpp4-glo protease assay - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

99
Cell Signaling Technology Inc pcmv myc dpp 4 cdna
Linagliptin (LGT) has neutral effects on body weight and aortic advanced glycation end-products (AGE). a WD feeding for 4 months resulted in significant weight gain in both the cohorts. b Plasma <t>DPP-4</t> activity was significantly decreased with LGT treatment. c AGE immunostaining in aorta was significantly increased in WDC. LGT treatment did not decrease it significantly. Quantification and representative images shown. Values are mean ± SE. CDC control diet control, CDL control diet linagliptin, WDC western diet control, WDL western diet linagliptin. Post-hoc comparisons within a time point; *p < 0.05 CDC vs WDC; # p < 0.05 CDC vs CDL; † p < 0.05 WDC vs WDL. Scale bars represent 50 mμ
Pcmv Myc Dpp 4 Cdna, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pcmv myc dpp 4 cdna/product/Cell Signaling Technology Inc
Average 99 stars, based on 1 article reviews
pcmv myc dpp 4 cdna - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier

92
Boster Bio serum cd26
<t>CD26</t> serum levels in patients with gastric cancer ( n = 30) and in control healthy individuals ( n = 24). Patients serum CD26 levels: 557.7 ± 118.3 pg/mL; control serum CD26 levels: 703.4 ± 170.3 pg/mL. * p = 0.001 by unpaired t test
Serum Cd26, supplied by Boster Bio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/serum cd26/product/Boster Bio
Average 92 stars, based on 1 article reviews
serum cd26 - by Bioz Stars, 2026-05
92/100 stars
  Buy from Supplier

90
Drucker Diagnostics dpp-4 inhibitors
<t>CD26</t> serum levels in patients with gastric cancer ( n = 30) and in control healthy individuals ( n = 24). Patients serum CD26 levels: 557.7 ± 118.3 pg/mL; control serum CD26 levels: 703.4 ± 170.3 pg/mL. * p = 0.001 by unpaired t test
Dpp 4 Inhibitors, supplied by Drucker Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dpp-4 inhibitors/product/Drucker Diagnostics
Average 90 stars, based on 1 article reviews
dpp-4 inhibitors - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

93
Cell Signaling Technology Inc dpp4 cd26 rabbit
<t>CD26</t> serum levels in patients with gastric cancer ( n = 30) and in control healthy individuals ( n = 24). Patients serum CD26 levels: 557.7 ± 118.3 pg/mL; control serum CD26 levels: 703.4 ± 170.3 pg/mL. * p = 0.001 by unpaired t test
Dpp4 Cd26 Rabbit, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dpp4 cd26 rabbit/product/Cell Signaling Technology Inc
Average 93 stars, based on 1 article reviews
dpp4 cd26 rabbit - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

90
MicroChem corp cd26 developing solution
<t>CD26</t> serum levels in patients with gastric cancer ( n = 30) and in control healthy individuals ( n = 24). Patients serum CD26 levels: 557.7 ± 118.3 pg/mL; control serum CD26 levels: 703.4 ± 170.3 pg/mL. * p = 0.001 by unpaired t test
Cd26 Developing Solution, supplied by MicroChem corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd26 developing solution/product/MicroChem corp
Average 90 stars, based on 1 article reviews
cd26 developing solution - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Shipley Corporation a concentrated cd26 solution
<t>CD26</t> serum levels in patients with gastric cancer ( n = 30) and in control healthy individuals ( n = 24). Patients serum CD26 levels: 557.7 ± 118.3 pg/mL; control serum CD26 levels: 703.4 ± 170.3 pg/mL. * p = 0.001 by unpaired t test
A Concentrated Cd26 Solution, supplied by Shipley Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/a concentrated cd26 solution/product/Shipley Corporation
Average 90 stars, based on 1 article reviews
a concentrated cd26 solution - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


Linagliptin (LGT) has neutral effects on body weight and aortic advanced glycation end-products (AGE). a WD feeding for 4 months resulted in significant weight gain in both the cohorts. b Plasma DPP-4 activity was significantly decreased with LGT treatment. c AGE immunostaining in aorta was significantly increased in WDC. LGT treatment did not decrease it significantly. Quantification and representative images shown. Values are mean ± SE. CDC control diet control, CDL control diet linagliptin, WDC western diet control, WDL western diet linagliptin. Post-hoc comparisons within a time point; *p < 0.05 CDC vs WDC; # p < 0.05 CDC vs CDL; † p < 0.05 WDC vs WDL. Scale bars represent 50 mμ

Journal: Cardiovascular Diabetology

Article Title: Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice

doi: 10.1186/s12933-016-0414-5

Figure Lengend Snippet: Linagliptin (LGT) has neutral effects on body weight and aortic advanced glycation end-products (AGE). a WD feeding for 4 months resulted in significant weight gain in both the cohorts. b Plasma DPP-4 activity was significantly decreased with LGT treatment. c AGE immunostaining in aorta was significantly increased in WDC. LGT treatment did not decrease it significantly. Quantification and representative images shown. Values are mean ± SE. CDC control diet control, CDL control diet linagliptin, WDC western diet control, WDL western diet linagliptin. Post-hoc comparisons within a time point; *p < 0.05 CDC vs WDC; # p < 0.05 CDC vs CDL; † p < 0.05 WDC vs WDL. Scale bars represent 50 mμ

Article Snippet: 20 μL plasma was diluted in DPP-4 assay buffer and substrate, 200 M H-Ala-Pro-AFC (I-1680; Bachem), was added.

Techniques: Activity Assay, Immunostaining, Western Blot

WD feeding causes a , b peri-aortic fibrosis and ( c , d ) medial thickening which is ameliorated by the DPP-4 inhibitor, LGT. a Picro sirius red and b Verhoeff-von Gieson staining. Values are mean ± SE. CDC control diet control, CDL control diet linagliptin, WDC western diet control and WDL western diet linagliptin. Post-hoc comparisons within a time point; *p < 0.05 CDC vs WDC; † p < 0.05 WDC vs WDL

Journal: Cardiovascular Diabetology

Article Title: Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice

doi: 10.1186/s12933-016-0414-5

Figure Lengend Snippet: WD feeding causes a , b peri-aortic fibrosis and ( c , d ) medial thickening which is ameliorated by the DPP-4 inhibitor, LGT. a Picro sirius red and b Verhoeff-von Gieson staining. Values are mean ± SE. CDC control diet control, CDL control diet linagliptin, WDC western diet control and WDL western diet linagliptin. Post-hoc comparisons within a time point; *p < 0.05 CDC vs WDC; † p < 0.05 WDC vs WDL

Article Snippet: 20 μL plasma was diluted in DPP-4 assay buffer and substrate, 200 M H-Ala-Pro-AFC (I-1680; Bachem), was added.

Techniques: Staining, Western Blot

WD feeding induced aortic oxidative stress is ameliorated with DPP-4 inhibition. a 3-nitrotyrosine staining; b EC 3-nitrotyrosine; c VSMC 3-nitrotyrosine. Values are mean ± SE. CDC control diet control, CDL control diet linagliptin, WDC western diet control and WDL western diet linagliptin. Post-hoc comparisons within a time point; *p < 0 0.05 CDC vs WDC; † p < 0.05 WDC vs WDL

Journal: Cardiovascular Diabetology

Article Title: Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice

doi: 10.1186/s12933-016-0414-5

Figure Lengend Snippet: WD feeding induced aortic oxidative stress is ameliorated with DPP-4 inhibition. a 3-nitrotyrosine staining; b EC 3-nitrotyrosine; c VSMC 3-nitrotyrosine. Values are mean ± SE. CDC control diet control, CDL control diet linagliptin, WDC western diet control and WDL western diet linagliptin. Post-hoc comparisons within a time point; *p < 0 0.05 CDC vs WDC; † p < 0.05 WDC vs WDL

Article Snippet: 20 μL plasma was diluted in DPP-4 assay buffer and substrate, 200 M H-Ala-Pro-AFC (I-1680; Bachem), was added.

Techniques: Inhibition, Staining, Western Blot

WD feeding induced changes in FGF-23 and Klotho expression are restored by DPP-4 inhibition. a FGF-23 staining; b Endothelial FGF-23; c Adventitia FGF-23; d Endothelial klotho staining; e Endothelial klotho staining f Adventitia klotho staining; Average gray intensities in the different cohorts. Values are mean ± SE. CDC control diet control, CDL control diet linagliptin, WDC western diet control and WDL western diet linagliptin. Post-hoc comparisons within a time point; *p < 0 0.05 CDC vs WDC; † p < 0.05 WDC vs WDL; # p < 0.05 CDC vs CDL. Scale bars represent 50 mμ

Journal: Cardiovascular Diabetology

Article Title: Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice

doi: 10.1186/s12933-016-0414-5

Figure Lengend Snippet: WD feeding induced changes in FGF-23 and Klotho expression are restored by DPP-4 inhibition. a FGF-23 staining; b Endothelial FGF-23; c Adventitia FGF-23; d Endothelial klotho staining; e Endothelial klotho staining f Adventitia klotho staining; Average gray intensities in the different cohorts. Values are mean ± SE. CDC control diet control, CDL control diet linagliptin, WDC western diet control and WDL western diet linagliptin. Post-hoc comparisons within a time point; *p < 0 0.05 CDC vs WDC; † p < 0.05 WDC vs WDL; # p < 0.05 CDC vs CDL. Scale bars represent 50 mμ

Article Snippet: 20 μL plasma was diluted in DPP-4 assay buffer and substrate, 200 M H-Ala-Pro-AFC (I-1680; Bachem), was added.

Techniques: Expressing, Inhibition, Staining, Western Blot

CD26 serum levels in patients with gastric cancer ( n = 30) and in control healthy individuals ( n = 24). Patients serum CD26 levels: 557.7 ± 118.3 pg/mL; control serum CD26 levels: 703.4 ± 170.3 pg/mL. * p = 0.001 by unpaired t test

Journal: BMC Cancer

Article Title: Serum CD26 levels in patients with gastric cancer: a novel potential diagnostic marker

doi: 10.1186/s12885-015-1757-0

Figure Lengend Snippet: CD26 serum levels in patients with gastric cancer ( n = 30) and in control healthy individuals ( n = 24). Patients serum CD26 levels: 557.7 ± 118.3 pg/mL; control serum CD26 levels: 703.4 ± 170.3 pg/mL. * p = 0.001 by unpaired t test

Article Snippet: The concentration of serum CD26 were analyzed using a specific immunoassays (Human CD26/DPP4 ELISA Kit, Boster biological technology, Pleasanton, CA) ELISAs were performed according to the manufacturer’s instructions: mean values of duplicated measurements were calculated and a sigmoid-shaped standard curve was determined by simultaneously analyzing a dilution series of standard samples.

Techniques: Control